JPM: Already prepping for Alzheimer's launch, Biogen scouts 'top talent' and talks pricing

Biogen hasn't even filed its FDA application for controversial Alzheimer's drug aducanumab yet. But it's already started gearing up for a launch, recruiting across biopharma for "top talent" for its rollout teams, building up manufacturing and talking to experts about one key number—price.